Innovative medicines to extend healthy lifespan.
We extend healthy lifespan through innovative medicines. Our approach centres around developing medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Pioneering Prevention for
A longer healthspan
Reduced chronic
disease burden
A healthier future
Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.
Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life.
By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.
Multiple Clinical
Medicines from 2024
On track to have five medicines in Phase I or II trials by 2025. These therapies target aging mechanisms, offering early disease intervention.
Innovating across
modalities
Our expert team develops treatments using small molecules, biologics, and cell therapies, focusing on aging’s core pathways to impact various age-related conditions.
Longevity at the core
Our primary goal is prevention, with the notable advantage of potentially increasing lifespan by addressing fundamental aging processes.
OUR TEAM
World-class R&D Leadership
Powered by an unrivaled drug development team, we leverage cutting-edge data science approaches to unlock successful drugs in the aging and longevity space. Our team brings together over 150 years of combined pharmaceutical R&D experience and boasts multiple drug approvals.
Our leadership has an unrivalled track record for delivering value.
OUR TEAM
World-class R&D Leadership
Powered by an unrivaled drug development team, we leverage cutting-edge data science approaches to unlock successful drugs in the aging and longevity space. Our team brings together over 150 years of combined pharmaceutical R&D experience and boasts multiple drug approvals.
Our leadership has an unrivalled track record for delivering value.
IN THE NEWS
Our latest developments
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership
Incredible week at Abu Dhabi Global Health Week
M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence
Relation Therapeutics announces two strategic collaborations with GSK to the tune of $300m
Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration
Hevolution Foundation
WHX Dubai
Buck Institute for Research on Aging
Morphoceuticals
